Neurological

Prevalence

38224.7 / 100K

Incidence

10843.7 / 100K/yr

9 drugs in development·8 companies·1 clinical trial

Drug Pipeline by Phase

Approved(2)

Drug	Company
miplyffa	XOMA Royalty Corporation (XOMA)
miplyffa capsules as an orally delivered treatment	ZEVRA THERAPEUTICS, INC. (ZVRA)

Phase 2(2)

Drug	Company
cemdomespib	REATA PHARMACEUTICALS INC (RETA)
rta 901	REATA PHARMACEUTICALS INC (RETA)

Phase 1(2)

Drug	Company
LP659	Longboard Pharmaceuticals, Inc. (LBPH)
sig-005	Sigilon Therapeutics, Inc. (SGTX)

Preclinical(3)

Drug	Company
gene therapy products	ClearPoint Neuro Inc. (CLPT)
neurohub	BRAIN SCIENTIFIC INC. (BRSF)
phoenix neuro	Phoenix Life Sciences International Limited. (PLSI)

BioSniper tracks 9 drugs in development for Neurological across 8 companies.

There are 1 clinical trial targeting Neurological tracked by BioSniper.

The estimated prevalence of Neurological is approximately 38224.7 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.